Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085689110> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3085689110 endingPage "S21" @default.
- W3085689110 startingPage "S20" @default.
- W3085689110 abstract "The U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1) as a standard second-line treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) on February 22, 2013. The purpose of this study was to assess the treatment patterns and sequences used in HER2+/hormone receptor-negative (HR-) mBC patients in the real-world setting following T-DM1 approval. We examined TriNetX electronic health record (EHR) data to conduct a retrospective cohort study of 2,362 eligible patients enrolled in 24 health care organizations (HCOs) across the U.S. between February 22, 2013 and March 30, 2020. Among all available anti-HER2 regimens, trastuzumab (H, 25%) was used most frequently, followed by trastuzumab/pertuzumab/taxane (THP, 23%) and trastuzumab/pertuzumab/taxane/carboplatin (TCHP, 21%). In the first-line setting, THP (20%), TCHP (20%) and trastuzumab (H,17%) are the three most common regimens. In the second-line setting, T-DM1 (20%) was used most frequently, followed by trastuzumab (14%) and other chemotherapies (10%). In the third-line setting, trastuzumab (H, 23%) was used most frequently, followed by HP (9%) and T-DM1 (9%). In terms of the sequence of treatments, THP followed by T-DM1 was the most common sequence, with the highest percentage of patients continuing to subsequent lines of therapy. Subgroup analysis comparing prescription patterns in patients 18-65 years versus ≥66 years showed similar results. The real-world landscape of HER2+ mBC treatment is consistent with the National Comprehensive Cancer Network (NCCN) clinical guidelines. Since most patients receive T-DM1 after THP, subsequent real-world studies may help clarify whether the effectiveness and safety of this sequence is similar to that reported in clinical trials." @default.
- W3085689110 created "2020-09-21" @default.
- W3085689110 creator A5001986733 @default.
- W3085689110 creator A5017100241 @default.
- W3085689110 creator A5024732211 @default.
- W3085689110 creator A5029591394 @default.
- W3085689110 creator A5031887194 @default.
- W3085689110 creator A5054784898 @default.
- W3085689110 creator A5064315491 @default.
- W3085689110 date "2020-09-01" @default.
- W3085689110 modified "2023-10-16" @default.
- W3085689110 title "PCN83 Real-World Prescription Patterns of HER2+/HR- Metastatic Breast Cancer Patients after Ado-Trastuzumab Emtansine Approval: A Retrospective Cohort Study Using Electronic Health Record DATA with Cancer Registries" @default.
- W3085689110 doi "https://doi.org/10.1016/j.vhri.2020.07.133" @default.
- W3085689110 hasPublicationYear "2020" @default.
- W3085689110 type Work @default.
- W3085689110 sameAs 3085689110 @default.
- W3085689110 citedByCount "0" @default.
- W3085689110 crossrefType "journal-article" @default.
- W3085689110 hasAuthorship W3085689110A5001986733 @default.
- W3085689110 hasAuthorship W3085689110A5017100241 @default.
- W3085689110 hasAuthorship W3085689110A5024732211 @default.
- W3085689110 hasAuthorship W3085689110A5029591394 @default.
- W3085689110 hasAuthorship W3085689110A5031887194 @default.
- W3085689110 hasAuthorship W3085689110A5054784898 @default.
- W3085689110 hasAuthorship W3085689110A5064315491 @default.
- W3085689110 hasBestOaLocation W30856891101 @default.
- W3085689110 hasConcept C121608353 @default.
- W3085689110 hasConcept C126322002 @default.
- W3085689110 hasConcept C143998085 @default.
- W3085689110 hasConcept C167135981 @default.
- W3085689110 hasConcept C2775930923 @default.
- W3085689110 hasConcept C2777511904 @default.
- W3085689110 hasConcept C2778087150 @default.
- W3085689110 hasConcept C2779786085 @default.
- W3085689110 hasConcept C2781164504 @default.
- W3085689110 hasConcept C530470458 @default.
- W3085689110 hasConcept C71924100 @default.
- W3085689110 hasConcept C72563966 @default.
- W3085689110 hasConceptScore W3085689110C121608353 @default.
- W3085689110 hasConceptScore W3085689110C126322002 @default.
- W3085689110 hasConceptScore W3085689110C143998085 @default.
- W3085689110 hasConceptScore W3085689110C167135981 @default.
- W3085689110 hasConceptScore W3085689110C2775930923 @default.
- W3085689110 hasConceptScore W3085689110C2777511904 @default.
- W3085689110 hasConceptScore W3085689110C2778087150 @default.
- W3085689110 hasConceptScore W3085689110C2779786085 @default.
- W3085689110 hasConceptScore W3085689110C2781164504 @default.
- W3085689110 hasConceptScore W3085689110C530470458 @default.
- W3085689110 hasConceptScore W3085689110C71924100 @default.
- W3085689110 hasConceptScore W3085689110C72563966 @default.
- W3085689110 hasLocation W30856891101 @default.
- W3085689110 hasOpenAccess W3085689110 @default.
- W3085689110 hasPrimaryLocation W30856891101 @default.
- W3085689110 hasRelatedWork W2552503324 @default.
- W3085689110 hasRelatedWork W2902290189 @default.
- W3085689110 hasRelatedWork W2946968461 @default.
- W3085689110 hasRelatedWork W2958119318 @default.
- W3085689110 hasRelatedWork W3033382144 @default.
- W3085689110 hasRelatedWork W3088751691 @default.
- W3085689110 hasRelatedWork W3100248540 @default.
- W3085689110 hasRelatedWork W3104544425 @default.
- W3085689110 hasRelatedWork W3123611170 @default.
- W3085689110 hasRelatedWork W4221053062 @default.
- W3085689110 hasVolume "22" @default.
- W3085689110 isParatext "false" @default.
- W3085689110 isRetracted "false" @default.
- W3085689110 magId "3085689110" @default.
- W3085689110 workType "article" @default.